High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, …
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing
Melinda A. Pruis, Floris H. Groenendijk, K. Sangeeta Badloe, Andrea Van Puffelen, Debbie Robbrecht, Winand N. M. Dinjens, Stefan Sleijfer, …
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. Van Oort, Winald R. Gerritsen, Jack A. Schalken, …
Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
Manouk K. Bos, Marcel Smid, Stefan Sleijfer & John W. M. Martens JCO Precision Oncology, 2022, DOI
Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features
Luan Nguyen, Arne Van Hoeck & Edwin Cuppen Nature Communications, 2022, DOI
A multi-platform reference for somatic structural variation detection
Jose Espejo Valle-Inclan, Nicolle J.M. Besselink, Ewart De Bruijn, Daniel L. Cameron, Jana Ebler, Joachim Kutzera, Stef Van Lieshout, Tobias …
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care
Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Åke Levin, Charles G. Mullighan, …
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients
Luuk J. Schipper, Kim Monkhorst, Kris G. Samsom, Linda J.W. Bosch, Petur Snaebjornsson, Hester Van Boven, Paul Roepman, Lizet E. …
Unscrambling cancer genomes via integrated analysis of structural variation and copy number
Charles Shale, Daniel L. Cameron, Jonathan Baber, Marie Wong, Mark J. Cowley, Anthony T. Papenfuss, Edwin Cuppen & Peter Priestley …
Substitution mutational signatures in whole-genome–sequenced cancers in the UK population
Andrea Degasperi, Xueqing Zou, Tauanne Dias Amarante, Andrea Martinez-Martinez, Gene Ching Chiek Koh, João M. L. Dias, Laura Heskin, Lucia …
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study
Mark P. Van Opijnen, Marike L. D. Broekman, Filip Y. F. De Vos, Edwin Cuppen, Jacobus J. M. Van Der …
Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice
Kris G Samsom, Luuk J Schipper, Paul Roepman, Linda Jw Bosch, Ferry Lalezari, Elisabeth G Klompenhouwer, Adrianus J De Langen, …
Zolang de behandelaar niet weet waar de primaire tumor zit, heeft hij ook geen gerichte behandelmogelijkheid en kan ook geen inschatting worden gegeven hoe lang iemand nog heeft.